Eisai Rides High On Expanded Oncology Capabilities, Enters Neglected Disease Foray

TOKYO - Two days after gaining U.S. FDA approval for its first in-house produced oncology product, Eisai continued its week of "firsts" with the announcement that it is the first Japanese pharmaceutical company to reach a supply agreement with the World Health Organization to combat a neglected tropical disease